Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002868042 | SCV003236020 | pathogenic | not provided | 2022-10-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Pro272Serfs*37) in the KCNJ11 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 119 amino acid(s) of the KCNJ11 protein. This variant is present in population databases (rs764143976, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with focal congenital hyperinsulinism of infancy (PMID: 17316607). This variant is also known as Ins1337T a1336t or c.813delinsTT. This variant disrupts a region of the KCNJ11 protein in which other variant(s) (p.Arg301Pro) have been determined to be pathogenic (PMID: 18250167, 21115269, 28787272). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |